Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Overview of attention for article published in Blood, July 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 3 news outlets
policy: 1 policy source
twitter: 23 X users

patent: 8 patents
f1000: 1 research highlight platform

Citations

dimensions_citation: 273 Dimensions

Readers on

mendeley: 175 Mendeley

Summary News Policy documents X Patents Research highlights Dimensions citations

So far, Altmetric has seen 28 X posts from 23 X users, with an upper bound of 174,273 followers.

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. #lymphoma #lymsm https://t.co/UfX0hy6CGy

24 Jan 2020

Reply Repost Favourite

@jonathanrockoff @VincentRK @US_FDA Zanubrutinib (Bruksina) may be poised to challenge ibrutinib for CLL and all other B cell lymphoma https://t.co/3dtDWY4lyo

15 Nov 2019

Reply Repost Favourite

RT @BloodJournal: Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in #C…

19 Sep 2019

Reply Repost Favourite

RT @BloodJournal: Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in #C…

19 Sep 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 24 additional X posts.